Qilian Formula Inhibits Tumor Cell Growth in a Bone Metastasis Model of Lung Cancer

被引:3
作者
Wang, Qin [1 ]
Zhao, Bei [2 ]
Li, Jiaqi [1 ]
Zhao, Jingwen [1 ]
Wang, Chengyan [1 ]
Li, Quanyao [1 ]
Yang, Wenxiao [1 ]
Xu, Ling [1 ,3 ,4 ]
Gong, Yabin [1 ,4 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western, Shanghai 200437, Peoples R China
[2] Shanghai Univ Tradit Chinese Med, Inst Interdisciplinary Integrat Med Res, Shanghai, Peoples R China
[3] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Tumor Inst Tradit Chinese Med, Shanghai, Peoples R China
[4] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese Med & Weste, Dept Oncol, 110 Ganhe Rd, Shanghai 200437, Peoples R China
关键词
Astragalus membranaceus and Ampelopsis japonica; Traditional Chinese Medicine; non-small cell lung cancer (NSCLC); bone metastasis; osteoclast formation; DENOSUMAB; MEDICINE; EXTRACT; PHASE-3;
D O I
10.1177/15347354231217274
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Bone metastasis is frequently common in advanced lung cancer with the major issue of a pathological fracture. Previous studies suggested that Astragalus membranaceus (Qi) and Ampelopsis japonica (Lian), which are used as folk medicine in China, have potential effects on inhibiting tumor growth and protecting bones, respectively. In this study, an experiment on the inhibitory effect of the Qilian formula (AAF) in vivo was designed to examine tumor growth in bone and osteoclast formation.Materials and Methods: The bone metastasis xenograft models were established by implanting NCI-H460-luc2 lung cancer cells into the right tibiae bones of mice. After confirming the model's viability through optical imaging 7 days post-implantation, 2 groups, namely the AAF group and the control group, were administered 0.3 mL of AAF extract (9 g/kg/day) or normal saline via intragastric delivery for a duration of 4 weeks. Throughout the study, we longitudinally assessed tumor burden, bone destruction, and weight-bearing capacity in vivo using reporter gene bioluminescence imaging (BLI), micro-CT, and dynamic weight-bearing (DWB) tests. Mechanistic insights were gained through Hematoxylin-eosin (H&E) staining, immunohistochemical (IHC) analysis, western blotting, and flow cytometry.Results: Qilian formula produced significant inhibition to the progress of bone destruction and tumor burden in the right tibiae bone in the treatment group. It was further evidenced by molecular imaging in vivo via small animal micro-CT and BLI with parametric quantification, characterizing significantly lower uptake of BLI signal in the treated tumor lesions and improving the pathological changes in the microstructure of bone. Furthermore, DWB tests revealed that Qilian formula treatment significantly maintained the weight-bearing capacity. According to immunohistochemical analysis, the effect of the Qilian formula appeared to involve the suppression of osteoclast formation by lower expression of the tartrate-resistant acid phosphatase. Cell apoptosis and death induction were evidenced by a higher percentage of Bal2,BAX and caspase 3 expressions of Qilian formula-treated tumor tissues.Conclusions: Our study demonstrated a significant inhibitory effect of the Qilian formula on the progression of osteolytic invasion in vivo by suppressing osteoclastogenesis and promoting apoptotic cell death.
引用
收藏
页数:12
相关论文
共 26 条
  • [1] Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Skeletal Metastases from Lung Cancer? A Systematic Review and Network Meta-analysis
    Bozzo, Anthony
    Deng, Jiawen
    Abbas, Umaima
    Bhasin, Richa
    Deodat, Marisa
    Wariach, Sajid
    Sanger, Stephanie
    Axelrod, Daniel
    Masrouha, Karim
    Turcotte, Robert
    Wilson, David
    Ghert, Michelle
    [J]. CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2021, 479 (09) : 2047 - 2057
  • [2] Integrins in Bone Metastasis Formation and Potential Therapeutic Implications
    Clezardin, P.
    [J]. CURRENT CANCER DRUG TARGETS, 2009, 9 (07) : 801 - 806
  • [3] BONEMETASTASIS: MECHANISMS, THERAPIES, AND BIOMARKERS
    Clezardin, Philippe
    Coleman, Rob
    Puppo, Margherita
    Ottewell, Penelope
    Bonnelye, Edith
    Paycha, Frederic
    Confavreux, Cyrille B.
    Holen, Ingunn
    [J]. PHYSIOLOGICAL REVIEWS, 2021, 101 (03) : 797 - 855
  • [4] Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial
    Coleman, Robert
    Finkelstein, Dianne M.
    Barrios, Carlos
    Martin, Miguel
    Iwata, Hiroji
    Hegg, Roberto
    Glaspy, John
    Montano Perianez, Alvaro
    Tonkin, Katia
    Deleu, Ines
    Sohn, Joohyuk
    Crown, John
    Delaloge, Suzette
    Dai, Tian
    Zhou, Ying
    Jandial, Danielle
    Chan, Arlene
    [J]. LANCET ONCOLOGY, 2020, 21 (01) : 60 - 72
  • [5] Duivenvoorden WCM, 1999, CLIN EXP METASTAS, V17, P27
  • [6] Osteoblasts remotely supply lung tumors with cancer-promoting SiglecFhigh neutrophils
    Engblom, Camilla
    Pfirschke, Christina
    Zilionis, Rapolas
    Martins, Janaina Da Silva
    Bos, Stijn A.
    Courties, Gabriel
    Rickelt, Steffen
    Severe, Nicolas
    Baryawno, Ninib
    Faget, Julien
    Savova, Virginia
    Zemmour, David
    Kline, Jaclyn
    Siwicki, Marie
    Garris, Christopher
    Pucci, Ferdinando
    Liao, Hsin-Wei
    Lin, Yi-Jang
    Newton, Andita
    Yaghi, Omar K.
    Iwamoto, Yoshiko
    Tricot, Benoit
    Wojtkiewicz, Gregory R.
    Nahrendorf, Matthias
    Cortez-Retamozo, Virna
    Meylan, Etienne
    Hynes, Richard O.
    Demay, Marie
    Klein, Allon
    Bredella, Miriam A.
    Scadden, David T.
    Weissleder, Ralph
    Pittet, Mikael J.
    [J]. SCIENCE, 2017, 358 (6367)
  • [7] The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma
    Gan, Zhen Ying
    Fitter, Stephen
    Vandyke, Kate
    To, Luen B.
    Zannettino, Andrew C. W.
    Martin, Sally K.
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 94 (04) : 343 - 354
  • [8] Therapeutic Anabolic and Anticatabolic Benefits of Natural Chinese Medicines for the Treatment of Osteoporosis
    He, Jianbo
    Li, Xiaojuan
    Wang, Ziyi
    Bennett, Samuel
    Chen, Kai
    Xiao, Zhifeng
    Zhan, Jiheng
    Chen, Shudong
    Hou, Yu
    Chen, Junhao
    Wang, Shaofang
    Xu, Jiake
    Lin, Dingkun
    [J]. FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [9] Endocrine aspects of bone metastases
    Hofbauer, Lorenz C.
    Rachner, Tilman D.
    Coleman, Robert E.
    Jakob, Franz
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (06) : 500 - 512
  • [10] Jiaxiang L., 2003, Bull Med Res, V03